Mallinckrodt Pharma IP Trading D.a.c.

Profibrix B.v.

Fibriant B.v.

Mallinckrodt Oharma IP Trading D.a.c.

Jacob Koopman

Joseph Grimbergen

Abraham Bout

Glen Martyn

Miranda Weggeman

Glen Patrick Martyn

The present invention relates to compositions comprising fibrinogen gamma prime variants for use in the treatment or prevention of an infection and methods of administering the composition. The fibrinogen gamma prime variants in the composition comprise at least one fibrinogen gamma prime polypeptide chain. The compositions for use according to the invention may also comprise other fibrinogen variants. Compositions comprising fibrinogen gamma prime variants according to the invention improve survival time after infection up to more than 200 percent compared to WT fibrinogen. They may be used both therapeutically and prophylactically.

Therapeutic uses of fibrinogen gamma prime variants

The present invention relates to nucleotide sequences encoding a fibrinogen alpha, beta or gamma chain. The sequences are optimized for expression in a eukaryotic cell culture system. Such optimized nucleotide sequences allow for the efficient expression of recombinant fibrinogen and variants thereof in intact form in a eukaryotic cell culture system.

Recombinant fibrinogen

The present invention relates to extravascular supports. In particular, to extravascular supports which are used in vein grafting. More in particular, it relates to extravascular supports which are biodegradable.

Biodegradable extravascular stent

The present invention relates to fibrinogen preparations enriched in &#x3b1;-extended fibrinogen. Compositions comprising such preparations show improved clotting properties compared to preparations based on HMW Fib which typically contain no or only low amounts of &#x3b1;-extended fibrinogen. In particular, clot formation time and the clot strength of a clot made by &#x3b1;-extended fibrinogen are improved. In addition, plasmin-mediated degradation of &#x3b1;-extended fibrinogen is reduced as compared to plasma derived fibrinogen.

Fibrinogen preparations enriched in fibrinogen with an extended alpha chain

A fibrin sealant comprises a mixture of first microparticles that comprise fibrinogen, second microparticles that comprise thrombin, and additive material. The additive material may be particulate, and may be, for instance, a biocompatible, water-absorbent, material, a biocompatible, water-swellable material, a biocompatible, water-insoluble material, a polysaccharide or silica.

Dry powder fibrin sealant

Dry powder compositions are useful in the treatment or prevention of tissue adhesions during or after surgery or during wound therapy. The dry powder compositions may contain trehalose. The dry powder compositions may be fibrin sealant compositions comprising fibrinogen and/or thrombin.

Treatment of tissue adhesion

The present invention relates to a dry powder fibrin sealant which comprises a mixture of fibrinogen and thrombin for use in surgery, trauma and other wounds or injuries. It further relates to novel formulations comprising said dry powder fibrin sealant for use in the treatment of wounds or for surgical intervention or as a topical hemostat.

Growing community of inventors

Leiderdorp, Netherlands

Jacob Koopman